How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses

Vinay Prasad, Sham Mailankody

Research output: Contribution to journalArticle

7 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)1860-1861
Number of pages2
JournalBlood
Volume126
Issue number15
DOIs
StatePublished - Oct 8 2015

Fingerprint

Quality-Adjusted Life Years
Hematologic Neoplasms
Antineoplastic Agents
Cost-Benefit Analysis
Quality of Life
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. / Prasad, Vinay; Mailankody, Sham.

In: Blood, Vol. 126, No. 15, 08.10.2015, p. 1860-1861.

Research output: Contribution to journalArticle

@article{cadce5ed86dc40558f0148602b623604,
title = "How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses",
author = "Vinay Prasad and Sham Mailankody",
year = "2015",
month = "10",
day = "8",
doi = "10.1182/blood-2015-07-657478",
language = "English (US)",
volume = "126",
pages = "1860--1861",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "15",

}

TY - JOUR

T1 - How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses

AU - Prasad, Vinay

AU - Mailankody, Sham

PY - 2015/10/8

Y1 - 2015/10/8

UR - http://www.scopus.com/inward/record.url?scp=84943599112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943599112&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-07-657478

DO - 10.1182/blood-2015-07-657478

M3 - Article

VL - 126

SP - 1860

EP - 1861

JO - Blood

JF - Blood

SN - 0006-4971

IS - 15

ER -